Strategic partnerships Stokes Pharmacy recently announced an exclusive partnership with the Bova Group in May 2024, expanding its distribution reach and access to cat owners in the US. This creates cross-selling opportunities with veterinary channels and pet care providers that serve similar customer bases.

Veterinary and human medicine The company specializes in compounded prescriptions for both human and veterinary patients, offering customized formulations. This positions Stokes to pursue targeted outreach to clinics, hospitals, and veterinary practices seeking tailored meds not readily available from standard suppliers.

Quality and compliance With rigorous in-house and contract microbiology and chemistry labs and adherence to USP standards (including sterility, endotoxins, and compounding guidelines), Stokes can be a preferred supplier for risk-averse buyers prioritizing product integrity and patient safety.

Expansive product lines The introduction of Epicur brand manufactured products alongside its customized formulations broadens its portfolio, enabling upsell to existing customers and attracting new buyers who value a wider, reliable product catalog under one partner.

Financial scale and growth With reported revenue in the 50 to 100 million range and a mid-sized employee base, Stokes presents a solid growth profile suitable for sales initiatives targeting mid-market healthcare distributors, veterinary suppliers, and specialty pharmacies seeking scalable partners.